IQUIX Drug Patent Profile

When do Iquix patents expire, and when can generic versions of Iquix launch?

Iquix is a drug marketed by Santen and is included in one NDA.

The generic ingredient in IQUIX is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Iquix

A generic version of IQUIX was approved as levofloxacin by RISING on December 20^th, 2010.

Summary for IQUIX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	83
Patent Applications:	800
DailyMed Link:	IQUIX at DailyMed

US Patents and Regulatory Information for IQUIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santen	IQUIX	levofloxacin	SOLUTION/DROPS;OPHTHALMIC	021571-001	Mar 1, 2004		DISCN	Yes	No

Expired US Patents for IQUIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Santen	IQUIX	levofloxacin	SOLUTION/DROPS;OPHTHALMIC	021571-001	Mar 1, 2004

EU/EMA Drug Approvals for IQUIX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A	Quinsair	levofloxacin	EMEA/H/C/002789Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2015-03-25

International Patents for IQUIX

See the table below for patents covering IQUIX around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	166131
Finland	884331
Yugoslavia	186788
Latvia	5805	Optiski aktivie piridobenzoksazina atvasinajumi
Japan	H04364185	PYRIDOBENZOXAZINE DERIVATIVE
Japan	S62252790	PYRIDOBENZOXAZINE DERIVATIVE

Supplementary Protection Certificates for IQUIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0206283	SPC/GB97/085	United Kingdom		PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
0206283	C980016	Netherlands		PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
0206283	98C0041	Belgium		PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606

IQUIX Market Analysis and Financial Projection

Last updated: February 11, 2026

What Are the Market Dynamics for IQUIX?

IQUIX, a pharmaceutical drug, operates within a competitive landscape characterized by several key factors:

• Indication and Patient Demographics: IQUIX targets specific indications such as oncology or infectious diseases, with market size driven by prevalence and unmet medical needs. For example, if IQUIX treats a particular cancer, the cost and access depend on the incidence rate and diagnostic accuracy.

• Competitive Positioning: Major competitors include drugs with similar mechanisms of action or therapeutic benefits. The entry of biosimilars or generics can impact IQUIX's market share, especially post-patent expiry.

• Pricing and Reimbursement: Pricing strategies depend on regulatory policies, payer negotiations, and value demonstration. Reimbursement levels directly influence sales potential across regions.

• Regulatory Environment: Approvals by agencies like the FDA or EMA govern market entry. Expedited pathways (e.g., Breakthrough Therapy, Priority Review) can accelerate commercialization, affecting market timing.

• Manufacturing and Supply Chain: Availability of raw materials, manufacturing capacity, and logistics influence market readiness and stability. Supply disruptions can affect sales timing and volume.

• Market Penetration Strategies: Partnerships, licensing, or direct sales models shape distribution and uptake, impacting revenue growth.

What Is the Financial Trajectory of IQUIX?

IQUIX's financial outlook hinges on several factors:

• Peak Sales Projections: Based on market size, competitive landscape, and pricing, analysts estimate peak annual sales. For drugs in niche markets, peak sales may range from $100 million to over a billion USD.

• Development and Commercialization Costs: R&D expenses for clinical trials, regulatory submissions, and initial marketing can total several hundred million dollars. For instance, bringing a biologic to market often involves costs exceeding $1 billion [1].

• Pricing Strategy: Setting a price per dose or treatment course influences revenue. High-cost therapies may face reimbursement hurdles but can command premium pricing if they demonstrate significant benefits.

• Market Adoption and Uptake: Speed and extent of adoption affect revenue timelines. Early engagement with key opinion leaders (KOLs) accelerates adoption.

• Regulatory Milestones: Approvals and labeling expansions can unlock additional revenue streams. Post-approval, urgent payers' negotiations can alter initial revenue forecasts.

• Patent and Exclusivity Periods: Patent life determines the duration of market exclusivity, typically 12-20 years from filing. Loss of exclusivity invites generic competition, affecting long-term revenue.

• Pipeline and Lifecycle Management: Development of next-generation formulations or combination therapies can extend market dominance.

Cost and Revenue Comparison to Similar Drugs

Aspect	IQUIX Potential Range	Similar Drugs (Examples)
Peak Annual Sales	$200 million – $1 billion	$400 million – $2 billion (e.g., Keytruda)
Development Cost	$500 million – $1.5 billion	$400 million – $1.2 billion
Patent Duration	12-20 years from filing	Similar range
Time to Market	7-12 years	8-12 years
Pricing per Treatment	$25,000 – $150,000 per course	Similar variations

Key Drivers and Risks

• Market Access: Reimbursement policies and payer acceptance can limit sales.

• Scientific Efficacy: Demonstrated clinical benefits affect adoption.

• Regulatory Delays: Unexpected delays can extend time-to-market.

• Competition: New entrants or biosimilars can erode market share.

• Manufacturing Reliability: Disruptions can impact supply and revenue.

Final Summary

IQUIX’s market success relies on targeting precisely defined populations, securing regulatory approvals quickly, and establishing durable patents. Its financial trajectory will depend on achieving commercial scale, managing costs, and defending market position once patents expire or biosimilars emerge.

Key Takeaways

• Market size and competitive landscape are critical for revenue potential.
• Forecasts for peak sales vary considerably but generally fall within hundreds of millions to over a billion USD.
• Development costs range from hundreds of millions to over a billion USD, with approval times spanning 7-12 years.
• Patent life and market exclusivity are key to maximizing long-term revenue.
• Reimbursement and payer policies significantly influence market access and sales progression.

FAQs

1. How does patent expiry affect IQUIX?
   Patent expiry typically leads to generic or biosimilar entry, reducing market exclusivity and significantly lowering revenues.

2. What competitive factors influence IQUIX’s market share?
   The strength of its clinical profile, pricing, reimbursement strategies, and patent protections determine market penetration.

3. What are typical development costs for drugs like IQUIX?
   Costs generally range from $500 million to over $1 billion, depending on the complexity and trial phases.

4. How long does it take for a new drug to reach peak sales?
   Usually 8-12 years from initiation to peak market penetration, depending on regulatory and adoption factors.

5. What regulatory pathways can accelerate IQUIX’s approval?
   Fast-track, Breakthrough Therapy, Priority Review, and Accelerated Approval programs expedite market access but require demonstrated significant benefit.

Sources

[1] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.